Number To Know…933
Novocure plans to enroll 933 patients in a trial of its Optune system for newly-diagnosed glioblastoma; the trial is designed to help Novocure get German reimbursement for the therapy.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.